Wegovy is one of a new class of weight loss drugs called GLP-1 receptor agonists, ... (€117.4 billion) by 2028, and shortages have been reported across the European Union since 2022.

Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of semaglutide has shown “exciting” results.

Novo Nordisk said European Union drug regulators support a label expansion for its blockbuster Wegovy drug to reflect its potential to reduce risk of major cardiovascular events including heart ...

(RTTNews) - Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy ...

European health officials are warning that the popular weight-loss drugs Ozempic and Wegovy can cause a potentially dangerous eye condition as a side effect.. The European Medicines Agency’s safety ...

The agency has also backed use of Wegovy to lower major heart risks and strokes in overweight or obese adults without ... has been authorized in the European Union to treat obesity since 2022.

Ozempic and Wegovy ingredient may reverse signs of liver disease. ... plans to seek accelerated approval from drug regulatory agencies in the United States and the European Union.

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the largest pharmaceutical companies, would pay ...

France won’t pay for weight loss drug Wegovy. What about other European countries? ... (€117.4 billion) by 2028, and shortages have been reported across the European Union since 2022.

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of semaglutide has shown “exciting” results. View on euronews ...